Elevation of one hour plasma glucose during oral glucose tolerance testing

Pediatric Pulmonology

Volumn 50, Issue 10, 2015, Pages 963-969

  Sheikh, Saba ^a   Putt, Mary E ^a   Forde, Kimberly A ^a,b   Rubenstein, Ronald C ^a   Kelly, Andrea ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cystic fibrosis; cystic fibrosis related diabetes; oral glucose tolerance test

Indexed keywords

GLUCOSE; GLUCOSE BLOOD LEVEL;

ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; ANALYSIS; BLOOD; FOLLOW UP; GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; BLOOD GLUCOSE; CHILD; COHORT STUDIES; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GLUCOSE TOLERANCE TEST; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 84941736537     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23237     Document Type: Article

References (33)

1. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W,. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626-1631.
2. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ,. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 46: 681-687.
3. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B,. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001; 32: 343-350.
4. Milla CE, Warwick WJ, Moran A,. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162: 891-895.
5. Milla CE, Billings J, Moran A,. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28: 2141-2144.
6. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H,. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009; 32: 1783-1788.
7. Moran A,. Diagnosis, screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep 2002; 2: 111-115.
8. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B,. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-2708.
9. Tofe S, Moreno JC, Maiz L, Alonso M, Escobar H, Barrio R,. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 2005; 152: 241-247.
10. Hadjiliadis D, Madill J, Chaparro C, Tsang A, Waddell TK, Singer LG, Hutcheon MA, Keshavjee S, Elizabeth Tullis D,. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant 2005; 19: 773-778.
11. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M,. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006; 29: RC1-4.
12. Minicucci L, Haupt M, Casciaro R, De Alessandri A, Bagnasco F, Lucidi V, Notarnicola S, Lorini R, Bertasi S, Raia V, et al., Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatr Diabetes 2012; 13: 197-202.
13. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS,. Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 2: 1603-1607.
14. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA,. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008; 31: 1650-1655.
15. Succurro E, Marini MA, Arturi F, Grembiale A, Lugara M, Andreozzi F, Sciacqua A, Lauro R, Hribal ML, Perticone F, et al., Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 2009; 207: 245-249.
16. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A,. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011; 34: 292-295.
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL,. CDC growth charts: United States. Adv Data 2000; 1-27.
18. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG, Jr,. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15: 75-88.
19. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
20. McIntyre K,. Gender and survival in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 692-697.
21. Ode KL, Frohnert B, Laguna T, Phillips J, Holme B, Regelmann W, Thomas W, Moran A,. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010; 11: 487-492.
22. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP,. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991; 118: 715-723.
23. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A,. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30: 1056-1061.
24. Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA,. Distinct beta-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012; 61: 447-453.
25. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, et al., Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802-810.
26. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
27. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC,. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
28. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE,. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288.
29. Shah BR, Hux JE,. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-513.
30. Saumon G, Martet G, Loiseau P,. Glucose transport and equilibrium across alveolar-airway barrier of rat. Am J Physiol 1996; 270: L183-L190.
31. Philips BJ, Redman J, Brennan A, Wood D, Holliman R, Baines D, Baker EH,. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax 2005; 60: 761-764.
32. Koziel H, Koziel MJ,. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am 1995; 9: 65-96.
33. Dennis RJ, Maldonado D, Rojas MX, Aschner P, Rondon M, Charry L, Casas A,. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med 2010; 10: 38.